Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited announced that all resolutions were passed at its Annual General Meeting, with significant support for the adoption of the Remuneration Report. The company’s Sofra technology platform, which targets inflammatory and autoimmune diseases, holds potential for significant market impact, given the projected growth in the autoimmune disease therapeutics and immuno-oncology markets.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company utilizes its proprietary Sofra and Chroma technology platforms to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.
Average Trading Volume: 109,444
Technical Sentiment Signal: Sell
Current Market Cap: A$26.3M
For an in-depth examination of NOX stock, go to TipRanks’ Overview page.